Clinical study of combination of application of Recombinant Human Interferon α2b Suppositories and Nifuratel Nystatin Soft Capsules in treatment of recurrent vulvovaginal candidiasis
XU Xiao-xian LI Shi-rong WU Hui-yin
Department of Pharmacy,Zhongshan Sanxiang Hospital,Guangdong Province,Zhongshan528463,China
Abstract:Objective To investigate the effect of combination of application of Recombinant Human Interferon α2b Suppositories and Nifuratel Nystatin Soft Capsules in the treatment of recurrent vulvovaginal candidiasis(RVVC). Methods Altogether 120 patients with RVVC who were treated in our hospital from May 2015 to April 2016 were randomly divided into observation group and control group,with 60 cases in each group.The control group was treated with the combination of Nifuratel Nystatin Soft Capsules and Fluconazole Dispersible Tablets;while,observation group was treated with the combination of recombinant human interferon α2b Suppositories and Nifuratel Nystatin Soft Capsules.The curative effect of the two groups were observed.Results The total effective rate of observation group was 96.7%,higher than that of control group(71.7%)(P<0.05);the adverse reaction rate of observation group and control group were 1.7%and 11.7%,with statistically significant difference(P<0.05);the 3-month and 6-month after drug withdrawal recurrence rate of observation group were 0 and 3.3%,significantly lower than those of control group(10.0%,25.0%)(P<0.05).Conclusion Combination of application of Recombinant Human Interferon α2b Suppositories and Nifuratel Nystatin Soft Capsules in the treatment of recurrent vulvovaginal candidiasis is helpful to improve the therapeutic effect and reduce the adverse reactions and recurrence rate,which achieves obvious curative effect.
徐晓贤 ;李世荣 ;吴会银. 重组人干扰素α2b栓联合硝夫太尔制霉菌素软胶囊治疗复发性外阴阴道假丝酵母菌病的临床研究[J]. 中国当代医药, 2017, 24(10): 96-98.
XU Xiao-xian;LI Shi-rong;WU Hui-yin. Clinical study of combination of application of Recombinant Human Interferon α2b Suppositories and Nifuratel Nystatin Soft Capsules in treatment of recurrent vulvovaginal candidiasis. 中国当代医药, 2017, 24(10): 96-98.